Head-To-Head Contrast: Rallybio (NASDAQ:RLYB) vs. Alector (NASDAQ:ALEC)

Alector (NASDAQ:ALEC) and Rallybio (NASDAQ:RLYB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Risk & Volatility

Alector has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500. Comparatively, Rallybio has a beta of -0.72, meaning that its stock price is 172% less volatile than the S&P 500.

Profitability

This table compares Alector and Rallybio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alector	-850.13%	-531.03%	-44.00%
Rallybio	-911.07%	-40.53%	-38.13%

Institutional and Insider Ownership

85.8% of Alector shares are owned by institutional investors. Comparatively, 90.3% of Rallybio shares are owned by institutional investors. 8.3% of Alector shares are owned by company insiders. Comparatively, 10.3% of Rallybio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Alector and Rallybio”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$21.05 million	10.16	-$142.93 million	($1.10)	-1.74
Rallybio	$646,000.00	139.19	-$8.98 million	($4.34)	-3.90

Rallybio has lower revenue, but higher earnings than Alector. Rallybio is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Alector and Rallybio, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	2	4	3	0	2.11
Rallybio	1	0	0	0	1.00

Alector presently has a consensus target price of $3.40, suggesting a potential upside of 77.55%. Given Alector’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Alector is more favorable than Rallybio.

Summary

Alector beats Rallybio on 8 of the 14 factors compared between the two stocks.

About Alector

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

About Rallybio

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.